English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduHighlights
- A recent analysis found limited research evaluating depression screening tools in patients with kidney failure.
- Many studies were small in size and had other shortcomings.
People with kidney failure experience depression at rates higher than the general population. Medicare requires routine depression screening for patients with kidney failure, but no clear guidance on which methods to use.
Karli Kondo, PhD (VA Portland Health Care System and Oregon Health & Science University) and her colleagues conducted a review to identify depression screening tools that are appropriate for patients with kidney failure, and to better understand the impact of depression screening in this population.
The investigators identified 16 relevant studies that evaluated the performance characteristics of depression assessment tools for patients with kidney failure. A tool called the Beck Depression Inventory II (BDI-II) was by far the most extensively studied, with 9 studies examining its performance. Other tools included the Cognitive Depression Index (CDI), the Center for Epidemiologic Studies – Depression Scale (CES-D), the Hospital Anxiety and Depression Scale – Depressive Subscale (HADS-D), the Geriatric Depression Scale-15 (GDS-15), the Hamilton Depression Rating Scale (Ham-D), the Patient Health Questionnaire 2 (PHQ-2), PHQ-9, and others.
“Our hope was that we’d find evidence that pointed to an optimal screening tool. This was optimistic of course, for if there was one that had strong evidence, it would already be in use,” said Dr. Kondo. “We also hoped that the we’d find some evidence to support the use of the tools that are common in practice. And we didn’t. The PHQ-2 and -9 are widely used in medical settings and are free. The CES-D is another that is commonly used. We found only one study each of the PHQ-9 and the CES-D, and no studies of the PHQ-2.”
Dr. Kondo noted that many of the studies were conducted overseas, and it’s unclear how applicable they are to patients in the United States. Many of the studies were small, and among the studies examining the same tools, there wasn’t much agreement in the cutoff values chosen to define depression and its severity.
An accompanying editorial notes that there are multiple practical considerations to take into account when considering the best screening tool to identify depression in patients with kidney failure on dialysis.
A Patient Voice also accompanies the study and provides the perspective of a veteran with kidney disease who was diagnosed with depression through the PHQ-9 tool.
Study co-authors include Jennifer Antick, PhD, Chelsea Ayers, MPH, Devan Kansagara, MD, MCR, and Pavan Chopra, MD.
Disclosures: The authors reported no financial disclosures.
The article, titled “Depression Screening Tools for Patients with Kidney Failure: A Systematic Review,” will appear online at http://cjasn.asnjournals.org/ on November 17, 2020, doi: 10.2215/CJN.05540420.
The editorial, titled, “Screening for Depression in People with Kidney Failure,” will appear online at http://cjasn.asnjournals.org/ on November 17, 2020, doi: 10.2215/CJN.16381020.
The Patient Voice editorial, titled, “Depression: A Side Effect of CKD,” will appear online at http://cjasn.asnjournals.org/ on November 17, 2020, doi: 10.2215/CJN.16411020.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.
# # #
